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Treatment of primary tumors of the liver as well as of liver
metastases arising from other primary tumors has been a chal-
lenge for many disciplines in oncology [1, 2]. Both diagnoses
used to be considered a lethal verdict, but things are definitely
changing for those patients without extrahepatic disease.
While liver metastases from colorectal carcinoma are
the leading cause of cancer morbidity and mortality in
Western society, hepatocellular carcinoma (HCC) ranks
number one in morbidity/mortality in many Asian and
African countries.
It is only a few decades ago that, for both conditions,
therapeutic nihilism was the rule. Great efforts have been
undertaken to develop better medical (i.e., chemotherapy)
therapies. For HCC this has completely failed, while
chemotherapy for metastatic colorectal cancer is also often
of limited success, despite the recent development of novel
active antineoplastic agents.
The diagnosis of HCC is often made at a time before
metastases have developed, while in colorectal carcinoma
metastases are confined to the liver in a significant propor-
tion of the patients. Therefore, there is a relative advantage in
comparison with other neoplasms that often harbor disease at
multiple sites.
In the past 5-10 years, resection of one to three liver
metastases resulted in a long-term patient survival of 20%
[3]. More recently, Kemeny et al., showed that these
patients may benefit from adding adjuvant postoperative
hepatic arterial chemotherapy [4]. However, many patients
with large unilateral disease were excluded from surgery as
they frequently appeared to have additional, often deeply
located non-resectable metastases in the contralateral lobe.
Similarly, resection of primary HCC is often not feasible,
due to the large tumor volume, the presence of multiple 
primary tumors, or concomitant liver cirrhosis.
In this issue of The Oncologist, Curley [5] as well as
Bilchik et al., [6] elegantly present their experience with
radiofrequency ablation (RFA) in both primary HCC and in
colorectal liver metastases. Although both authors discuss
the feasibility of the percutaneous approach, between the
lines it appears that each of them favor the laparoscopic or
open surgical approach which affords a better view of the
liver and the peritoneal surface, limits liver blood flow dur-
ing RFA whenever required, and this provides the opportu-
nity to implant an arterial infusion device, if appropriate.
We totally agree with both authors that resection is the
prime goal of the treatment in these patients. Nonetheless,
RFA is a great asset to be added to a multidisciplinary
approach. This technique, which is still in a developmental
phase, is associated with fewer complications when com-
pared with other methods such as cryosurgical ablation
(CSA), injection of ethanol, heat ablation using microwave
coagulation therapy, or laser-induced thermotherapy. Of
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note, the results presented by the authors have been
achieved without adjuvant hepatic arterial chemotherapy.
The size limits of the tumors permitting RFA may dif-
fer, with Curley mentioning a maximum of 5-6 cm and
Bilchik referring to a maximum diameter of 3-4 cm.
However, both authors agree that the limits are moving
upwards as newer RFA devices become available. While
resection is often out of the question for lesions lying close
to the hepatic artery, portal vein and branches of the hepatic
vein, RFA (not CSA) can still be applied in certain
instances. It appears that the endothelium is resistant to
RFA but not to CSA-induced damage. Margin-free resec-
tions cannot be obtained for lesions located at such sites,
but lesions have been destroyed successfully by RFA. Both
authors mention the advantage of temporary occlusion of
arterial blood flow while applying RFA as the temperature
within the lesion will reach much higher levels without a
tendency to drop immediately after reaching the peak level.
Amazingly, temperatures up to 90°C can be achieved at the
target site. Also, newer devices are rapidly becoming avail-
able, which may provide therapeutic opportunities for
patients with lesions up to 10 cm.
Although long-term observations are still not available,
this technique will definitely give the surgeon a helping
hand, and offers the patient better prospects. Patients for
whom surgical resection of a large lesion was contraindi-
cated because of additional lesions in the contralateral lobe,
have become candidates for surgery because of RFA.
Bilchik recommends routine placement of an arterial infu-
sion pump in all patients who undergo resection and/or
ablation, while Curley still views this as experimental. In
our institute we have recently applied a technique for
hepatic arterial infusion chemotherapy consisting of the
percutaneous placement of a catheter through the subcla-
vian artery, with the tip located in the hepatic artery and the
proximal end connected with a subcutaneously placed
access device (Port-A-Cath) in the upper chest wall. As the
percentage of recurrences will be reduced to approximately
50% with the multimodality approach, a catheter which can
be removed in the outpatient clinic at the end of the adju-
vant chemotherapy will offer great advantages for this
group of patients.
In summary, the two key articles in this issue of The
Oncologist focus on the value of RFA, a technique that
offers great benefit to both patients with metastatic colorec-
tal cancer and those with primary HCC. It is advisable to
keep this technique in the experienced surgical hands asso-
ciated with referral centers where they have experience
with the treatment of this group of challenging patients. The
standard approach may ultimately become surgical resec-
tion, RFA (with temporary occlusion of blood flow), fol-
lowed by hepatic arterial infusion chemotherapy with
fluoropyrimidines and, in the near future, in combination
with other cytotoxic agents.
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